NASDAQ · Medical - Devices

ANIK (ANIK) Stock

$19.61 -5.43% NASDAQ: ANIK Healthcare

Valuation

MetricValue
Price$19.61
Market Cap$262.44M
P/E Ratio-19.58
P/B Ratio1.38
P/S Ratio1.70
EPS (TTM)$0.00
52-Week High$19.61
52-Week Low$7.87
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-7.69%
ROA-5.79%
ROCE-7.69%
Gross Margin-9.73%
Operating Margin-9.73%
Net Margin-9.52%
Debt/Equity0.19
Current Ratio4.68

Annual Financials (USD)

Metric20212022202320242025
Revenue$148.0M$114.0M$121.0M$120.0M$113.0M
Operating Profit$3.0M$4.0M$1.0M$-5.0M$-11.0M
Net Profit$4.0M$-15.0M$-83.0M$-56.0M$-11.0M
EPS$0.28$-1.02$-5.64$-3.83$-0.76
Op Margin1.8%3.2%0.7%-4.3%-9.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$348.0M$349.0M$271.0M$203.0M$190.0M
Total Liabilities$60.0M$64.0M$58.0M$49.0M$47.0M
Cash$94.0M$86.0M$69.0M$56.0M$57.0M
Borrowings$21.0M$31.0M$28.0M$26.0M$24.0M

Latest News

Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026 GlobeNewswire · Jul 15, 2026 Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jun 5, 2026 President of Anika Therapeutics Picks Up 51% More Stock Simply Wall St. · May 3, 2026 TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues GlobeNewswire · Apr 30, 2026 Anika Therapeutics, Inc. Q1 2026 Earnings Call Summary Moby · Apr 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$8.0M$4.0M$-2.0M$5.0M$11.0M
Investing Cash Flow$-8.0M$-15.0M$-11.0M$-16.0M$-7.0M
Financing Cash Flow$-7.0M$-5.0M$-6.0M$-13.0M$-11.0M
Net Cash Flow$-1.0M$-8.0M$-13.0M$-16.0M$0
Free Cash Flow$3.0M$-3.0M$-7.0M$-2.0M$4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield0.52%
Quick Ratio3.37
Interest Coverage—
Return 1Y34.61%
Return 3Y-37.77%
Return 5Y-61.94%

Ownership

Insiders Held6.43%
Institutions Held94.77%
Institutions Float Held101.27%
Institutional HolderSharesReport Date
Blackrock Inc.1,594,8932026-03-31
Caligan Partners, LP1,435,1302026-03-31
Morgan Stanley872,0662026-03-31
Acadian Asset Management. LLC606,5442026-03-31
Vanguard Capital Management LLC605,7772026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANIX $3.48 -1.14% -8.00 $118.40M 0.00%
APYX $4.07 -1.21% -17.90 $171.39M 0.00%
ARAY $0.28 +0.81% -15.50 $33.90M 0.00%
AVR $8.28 +0.00% -2.56 $304.61M 0.00%
LNSR $5.25 -1.87% 6.53 $63.55M 0.00%

About ANIK

ANIK is led by CEO Stephen D. Griffin, employs 288 people, headquartered in US, publicly traded since 1993.

ANIK stock trades at $19.61 with a market capitalization of $262.44M. The stock is valued at a price-to-earnings (P/E) ratio of -19.58, price-to-book of 1.38, price-to-sales of 1.70. Over the past 52 weeks the stock has ranged between $7.87 and $19.61, and currently trades at its 52-week high.

On profitability, ANIK generates a return on equity (ROE) of -7.69%, return on capital employed of -7.69%, an operating margin of -9.73%, a net profit margin of -9.52%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides